[Specific circulating immune complexes in patients with hepatitis B].
Antigen specific hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) were measured in 109 cases of hepatitis B with positive HBsAg (among them, 49 cases were acute and 60 cases were chronic hepatitis), 96 cases of asymptomatic hepatitis B surface antigen carriers, and 95 cases of normal blood donors. The mean concentration (ng/ml) of HBsAg-CICs was 303.50 +/- 357.70, 319.26 +/- 334.35 and 179.66 +/- 234.26 for the first three groups respectively; and was negative in normal groups. The concentration of HBsAg-CICs were significantly higher in acute and chronic group when compared with the asymptomatic carrier's group, (p less than 0.02 and p less than 0.01, respectively). Longitudinal series studies showed a close correlation between the levels or changes of HBsAg-CICs and the activity of the disease; patients with persistent HBsAg-CICs had a poor prognosis; and this were true not only in acute but also in chronic hepatitis patients. The mean concentration of HBsAg-CICs was higher in patients with positive hepatitis B e antigen (HBeAg) than in negative; but lower in patients with hepatitis B e anti-body (anti-HBe) positive than in negative. The higher prevalence of HBsAg-CICs in sera among asymptomatic HBsAg carriers in our study might be related to the prevalence of HBeAg among Chinese carriers. Further more, because HBsAg-CICs was related to the activity and prognosis of hepatitis B, it is worthwhile reconsidering whether so called "healthy" carriers were really healthy when their sera HBsAg-CICs tested positive.
D000936:Antigen-Antibody Complex / Q000032:analysis*; D002353:Carrier State / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D011379:Prognosis
D000936:Antigen-Antibody Complex; D006514:Hepatitis B Surface Antigens